Related Experiment Video
Updated: Apr 26, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
19.8K
Triple-negative breast cancer: An institutional analysis
1Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Indian Journal of Cancer
|August 9, 2014
Summary
Triple-negative breast cancer (TNBC) affects younger women and presents as high-grade tumors. While TNBC significantly worsens relapse-free survival, its impact on overall survival is not statistically significant.
Area of Science:
- Oncology
- Breast Cancer Research
- Cancer Biomarkers
Background:
- Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR), and HER2/neu expression.
- TNBC is recognized as an independent prognostic factor associated with poorer patient survival outcomes.
Purpose of the Study:
- To compare the clinico-pathological characteristics of TNBC and non-TNBC patients.
- To evaluate and contrast treatment outcomes between TNBC and non-TNBC groups.
Main Methods:
- Retrospective analysis of 706 invasive breast cancer patients with available ER, PR, and HER2/neu status.
- Data collected between January 2007 and December 2011.
Main Results:
- TNBC identified in 21.9% of patients, associated with significantly younger median age (46.2 vs. 49.8 years) and higher proportion of high-grade tumors (43% vs. 24%).
- Median follow-up of 30 months revealed significantly lower three-year relapse-free survival (RFS) in TNBC patients (64% vs. 76%).
- Three-year overall survival (OS) was lower in TNBC but not statistically significant; younger age, higher nodal stage, and larger tumor size (>5 cm) correlated with poor outcomes.
Conclusions:
- TNBC is linked to younger age and high-grade tumors, representing 21.9% of breast cancers in the study cohort.
- Triple negativity proved to be a significant negative prognostic factor for RFS, but not for OS.
